EX-23.1 14 apre-20221231xex23d1.htm EX-23.1

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

​

We consent to the incorporation by reference in the following Registration Statements:

| (1) | Registration Statement (Form S-8 No. 333-234765) pertaining to the 2019 Equity Incentive Plan of Aprea Therapeutics, Inc.,

| (2) | Registration Statement (Form S-8 No. 333-250043) pertaining to the 2019 Equity Incentive Plan of Aprea Therapeutics, Inc.,

| (3) | Registration Statement (Form S-3/A No. 333-250041) of Aprea Therapeutics, Inc.,

| (4) | Registration Statement (Form S-8 No. 333-260884) pertaining to the 2019 Equity Incentive Plan of Aprea Therapeutics, Inc.,

| (5) | Registration Statement (Form S-8 No. 333-268816) pertaining to the 2019 Equity Incentive Plan of Aprea Therapeutics, Inc.,

| (6) | Registration Statement (Form S-8 No. 333-265411) pertaining to the Atrin Pharmaceuticals LLC 2016 Amended and Restated Equity Compensation Plan,

​

of our report dated March 30, 2023, with respect to the consolidated financial statements of Aprea Therapeutics, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2022.

​

​

/s/ Ernst & Young LLP

​

Iselin, New Jersey

March 30, 2023